News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Child developmental issues news

Show

From To
Child developmental issues
Antiretrovirals do not cause neurodevelopmental harm to uninfected infants

In the first five years of life the neurological development of HIV-exposed but uninfected infants, exposed to maternal antiretrovirals before and after birth and throughout breastfeeding, is comparable

Published
24 June 2019
By
Carole Leach-Lemens
Child developmental issues
Teens with HIV have similar cognitive outcomes to HIV-negative peers

Teens who were perinatally infected with HIV and received treatment have similar cognitive outcomes compared with their HIV-negative peers, according to research published in Clinical Infectious Diseases. However, researchers observed that HIV-positive adolescents had decreased executive functioning over time, suggestive of earlier brain damage.

Published
27 May 2019
From
Healio
Side-effects
A Promising Anti-HIV Drug Poses A Dilemma

The anti-HIV drug dolutegravir is effective — but may carry a risk for pregnant women. While women in wealthy countries are given choices about their medical care, for women in poor countries the situation is different. There aren't enough doctors and nurses to explain the risks and benefits of the new drug to every patient. The country may not have the resources to keep supplies of two different drugs on the shelves. And there is no consistent access to effective birth control.

Published
23 April 2019
From
NPR
Neurological and cognitive problems
Young people born with HIV more likely to have “mild” verbal memory test deficits if they have ever had an AIDS-defining condition

A study presented at this year’s Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle found that young people born with HIV performed worse when

Published
18 April 2019
By
Gus Cairns
Treatment guidelines
Avoiding Dolutegravir in Young Women With HIV: Time for a Rethink?

Total deaths for women with HIV and their children are projected to be lower with dolutegravir-based (Tivicay) antiretroviral therapy (ART) versus efavirenz-based (Sustiva) ART, a model-based analysis found.

Published
05 April 2019
From
MedPage Today
Hepatitis B
Sixfold increased risk of infant HIV infection and high rates of low birth weight among women with HIV/hepatitis B co-infection

Women with high levels of hepatitis B viraemia (>106IU/ml) who have co-infection with HIV had a more than sixfold increased risk of having infants with HIV infection

Published
12 March 2019
By
Carole Leach-Lemens
Child developmental issues
Neural tube defects and integrase inhibitors: still waiting for stronger evidence

Researchers are still unable to determine if exposure to integrase inhibitors around conception and in early pregnancy increases the risk of neural tube defects in infants, research

Published
07 March 2019
By
Keith Alcorn
Child developmental issues
South Africa urgently needs an antiretroviral pregnancy registry

With the dolutegravir roll-out around the corner, the time is now ripe for patients and activists to demand a prospective pregnancy registry for the whole of South Africa. Whether it is a new endeavour or piggy-backs on international efforts is a matter for debate, but it is the only way we can answer the question of dolutegravir’s safety with the minimum number of women being exposed to the drug. It’s the least that patients deserve.

Published
29 January 2019
From
Spotlight
Child developmental issues
Efavirenz in pregnancy is at least as safe as other antiretrovirals

An individual patient data analysis of almost 25,000 pregnancies in women living with HIV has found that the rate of birth defects following exposure to efavirenz was

Published
17 January 2019
By
Roger Pebody
HIV treatment
Top 10 HIV Clinical Developments of 2018

It's the beginning of the end. Not in some apocalyptic way, but rather in how we think about the prevention and management of HIV.

Published
20 December 2018
From
The Body Pro
← First12345...8Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.